Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes.

ABSTRACT:

Importance

Pregnant women were excluded from the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech) preauthorization trial. Therefore, observational data on vaccine safety for prenatally exposed newborns are critical to inform recommendations on maternal immunization.

Objective

To examine whether BNT162b2 mRNA vaccination during pregnancy is associated with adverse neonatal and early infant outcomes among the newborns.

Design, setting, and participants

Population-based cohort study comprising all singleton live births in March through September 2021, within a large state-mandated health care organization in Israel, followed up until October 31, 2021.

Exposure

Maternal BNT162b2 mRNA vaccination during pregnancy.

Main outcomes and measures

Ri

SUBMITTER: Goldshtein I 

PROVIDER: S-EPMC8832306 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature